Perioperative imaging predictors of tumor progression and pseudoprogression: A systematic review

IF 5.5 2区 医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2024-07-09 DOI:10.1016/j.critrevonc.2024.104445
{"title":"Perioperative imaging predictors of tumor progression and pseudoprogression: A systematic review","authors":"","doi":"10.1016/j.critrevonc.2024.104445","DOIUrl":null,"url":null,"abstract":"<div><p>In high-grade gliomas, pseudoprogression after radiation treatment might dramatically impact patient’s management. We searched for perioperative imaging predictors of pseudoprogression in high-grade gliomas according to PRISMA guidelines, using MEDLINE/Pubmed and Embase (until January 2024).</p><p>Study design, sample size, setting, diagnostic gold standard, imaging modalities and contrasts, and differences among variables or measures of diagnostic accuracy were recorded. Study quality was assessed through the QUADAS-2 tool.</p><p>Twelve studies (11 with MRI, one with PET; 1058 patients) were reviewed. Most studies used a retrospective design (9/12), and structural MRI (7/12). Studies were heterogeneous in metrics and diagnostic reference standards; patient selection bias was a frequent concern. Pseudoprogression and progression showed some significant group differences in perioperative imaging metrics, although often with substantial overlap. Radiomics showed moderate accuracy but requires further validation.</p><p>Current literature is scarce and limited by methodological concerns, highlighting the need of new predictors and multiparametric approaches.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"202 ","pages":"Article 104445"},"PeriodicalIF":5.5000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824001884/pdfft?md5=3be3ad78762e5022f47190cbf28a37b1&pid=1-s2.0-S1040842824001884-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824001884","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In high-grade gliomas, pseudoprogression after radiation treatment might dramatically impact patient’s management. We searched for perioperative imaging predictors of pseudoprogression in high-grade gliomas according to PRISMA guidelines, using MEDLINE/Pubmed and Embase (until January 2024).

Study design, sample size, setting, diagnostic gold standard, imaging modalities and contrasts, and differences among variables or measures of diagnostic accuracy were recorded. Study quality was assessed through the QUADAS-2 tool.

Twelve studies (11 with MRI, one with PET; 1058 patients) were reviewed. Most studies used a retrospective design (9/12), and structural MRI (7/12). Studies were heterogeneous in metrics and diagnostic reference standards; patient selection bias was a frequent concern. Pseudoprogression and progression showed some significant group differences in perioperative imaging metrics, although often with substantial overlap. Radiomics showed moderate accuracy but requires further validation.

Current literature is scarce and limited by methodological concerns, highlighting the need of new predictors and multiparametric approaches.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肿瘤进展和假性进展的围手术期成像预测因素:系统综述。
在高级别胶质瘤中,放疗后的假性进展可能会对患者的治疗产生重大影响。我们根据 PRISMA 指南,使用 MEDLINE/Pubmed 和 Embase(截至 2024 年 1 月)检索了高级别胶质瘤假性进展的围手术期影像学预测因素。记录了研究设计、样本大小、环境、诊断金标准、成像模式和对比度,以及变量之间的差异或诊断准确性的衡量标准。研究质量通过 QUADAS-2 工具进行评估。共审查了 12 项研究(11 项采用 MRI,1 项采用 PET;1058 名患者)。大多数研究采用回顾性设计(9/12)和结构性 MRI(7/12)。研究的指标和诊断参考标准不尽相同;患者选择偏倚是一个常见问题。假性进展和进展在围手术期成像指标方面显示出一些显著的组间差异,但往往存在大量重叠。放射组学显示出适度的准确性,但需要进一步验证。目前的文献很少,而且受到方法学问题的限制,因此需要新的预测指标和多参数方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
3.20%
发文量
213
审稿时长
55 days
期刊介绍: Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.
期刊最新文献
Editorial Board Erratum to “Unleashing precision: A review of targeted approaches in pleural mesothelioma” [Crit. Rev. Oncol./Hematol. 203C (2024) 104481] Corrigendum to “The emerging HER2 landscape in Colorectal Cancer: The key to unveil the future treatment algorithm?” [Crit. Rev. Oncol./Hematol. 204 (2024) 104515] Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404] Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1